IDEX Corporation

▲ Bull Case

• ◆HST reaccelerates to +7–8% sustained organic growth by FY2027, driven by destocking catch-up dynamics (instrument OEMs under-ordered during the trough and must rebuild buffer inventory) plus GLP-1 manufacturing scaling to ~$150M of incremental revenue by FY2028. This drives FY2027 adj. EPS to ~$10.50 vs. consensus $9.11.
• ◆EBITDA margin expands to 30.5% by FY2028 as HST volume returns to higher-margin mix and IBS productivity outpaces wage inflation. This is achievable per Step 09 base rates (Roper sustained +200 bps over 5 years) and represents +200 bps from current 28.4%.
• ◆M&A multiple re-rates to 27–28x adj. P/E (Danaher-light) as HST grows toward 45%+ of revenue and demonstrates Life Sciences-type recurring characteristics. Combined with EPS leverage, equity value reaches $280–310 per share — a ~40% premium to today.

▼ Bear Case

• ◆HST recovery stalls in 2026–2027 as academic research budgets remain pressured (NIH funding constraint, biotech VC drought) and instrument OEM order momentum proves to be a one-quarter Q1 2026 head-fake. HST organic falls back to +1–2% sustained, dragging consolidated organic to +2% and FY2027 adj. EPS to ~$8.30 vs. consensus $9.11.
• ◆PE-backed competitors continue to inflate niche industrial M&A multiples to 15–17x EBITDA, forcing IDEX to either pay up (destroying value vs. historical 13% IRR target) or sit on cash (foregoing growth). The M&A flywheel — the central long-term value driver — loses 100–200 bps of unlevered IRR.
• ◆Multiple de-rates to 20x adj. P/E as the market questions both the HST quality premium and the M&A model durability in a higher-for-longer rate environment (10Y UST sustained above 5%). Equity value falls to $150–175 per share — a ~25% drawdown from today.

“The Street is split on what P/E multiple IDEX should command, and the debate is functionally a referendum on HST quality and the M&A model. Bull camp (26–28x adj. P/E) treats IDEX as a Danaher-light life-sciences-adjacent compounder where HST (38% of revenue) deserves a multiple closer to Thermo Fisher / Danaher / Repligen, citing 40+ years of disciplined M&A and 45–50% tangible ROIC. Bear camp (20–22x adj. P/E) treats IDEX as ultimately a cyclical industrial whose acquisition-driven goodwill (60% of total assets) creates returns-on-capital risk, and whose hardware-centric model caps the multiple ceiling well below software/recurring-revenue peers. The current market price of $210 implies ~25x consensus FY2026E EPS — squarely in the middle. The next 4–6 quarters of HST organic prints will likely resolve this debate. A secondary debate concerns M&A model durability at >15% IRR given inflated industrial M&A market multiples.”

• ◆HST organic growth >7% for 2+ consecutive quarters (next print Q2 2026 in late July) — would validate destocking-resolution thesis and unlock 26x P/E re-rating; highest-impact near-term catalyst
• ◆IDEX management explicitly quantifies GLP-1 manufacturing exposure at investor day or earnings call (2026 Investor Day in Q3) — would shift GLP-1 from speculative to baseline, lifting consensus FY2027 EPS by $0.30–0.50
• ◆Acquisition announcement in $300–700M range at <14x EBITDA with clear IBS pathway — would validate M&A flywheel durability and resolve central long-term debate
• ◆Adj. EBITDA margin reaching 29.5%+ on TTM basis (next read Q4 2026 earnings) — would validate operating-leverage component of bull thesis
• ◆Dividend increase >8% at next annual board review — signals management confidence in earnings durability and continues 15+ year increase streak

• ◆HST destocking re-emergence or extension in H2 2026 — if instrument OEM orders re-soften, entire recovery thesis at risk; highest-impact near-term risk
• ◆M&A multiple inflation — if PE-backed competitors keep niche industrial multiples at 15–17x EBITDA, IDEX forced to choose between overpaying (destroying value) or under-deploying (foregoing growth)
• ◆Interest rate environment — sustained 10Y UST above 5% would push WACC above 8.5%, compressing DCF values by ~$15–20/share and industrial multiples broadly
• ◆Technology disruption in HST — chip-based microfluidics (MEMS) could displace some HST precision-pump applications over 5–10 year horizon, eroding moat
• ◆FX headwinds — ~45% of revenue is non-USD; 5% USD strengthening reduces reported revenue by ~$80–100M
• ◆Industrial recession — moderate recession could drive 8–12% organic decline; severe recession 15–20%; investment-grade balance sheet provides structural protection but not multiple insulation
• ◆Management succession risk — long-tenured team (CEO Ashleman since March 2021, average executive tenure 8–12 years) creates concentrated execution risk if multiple senior leaders depart